Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The selective estrogen receptor modulator tamoxifen is routinely used for treatment and prevention of estrogen-receptor-positive breast cancer. Studies of tamoxifen adherence suggest that over half of patients discontinue treatment before the recommended 5 years. We hypothesized that polymorphisms in CYP2D6, the enzyme responsible for tamoxifen activation, predict for tamoxifen discontinuation. Tamoxifen-treated women (n=297) were genotyped for CYP2D6 variants and assigned a ‘score’ based on predicted allele activities from 0 (no activity) to 2 (high activity). Correlation between CYP2D6 score and discontinuation rates at 4 months was tested. We observed a strong nonlinear correlation between higher CYP2D6 score and increased rates of discontinuation (r2=0.935, P=0.018). These data suggest that presence of active CYP2D6 alleles may predict for higher likelihood of tamoxifen discontinuation. Therefore, patients who may be most likely to benefit from tamoxifen may paradoxically be most likely to discontinue treatment prematurely.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
Horne, R., & Weinman, J. (1999) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(99)00057-4 · Cited by 2,201
Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040331 · Cited by 1,759
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer
Partridge, A. H., Wang, P. S., Winer, E. P., & Avorn, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.071 · Cited by 676
Intentional and non-intentional non-adherence to medication amongst breast cancer patients
Atkins, L., & Fallowfield, L. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.03.004 · Cited by 300
Adherence to endocrine therapy for breast cancer
Chlebowski, R. T., & Geller, M. L. (2006) · Oncology · doi:10.1159/000100444 · Cited by 251
Cited by
Murphy, C. C., Bartholomew, L. K., Carpentier, M. Y., Bluethmann, S. M., & Vernon, S. W. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2114-5 · Cited by 708
“Women with higher levels of CYPD26 were less likely to be adherent to and/or continue treatment [29, 39].”
Schneider, B. P., Wang, M., Radovich, M., Sledge, G. W., Badve, S., Thor, A., Flockhart, D. A., Hancock, B., Davidson, N., Gralow, J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1612 · Cited by 604
Self-citationKelly, C. M., Juurlink, D. N., Gomes, T., Duong-Hua, M., Pritchard, K. I., Austin, P. C., & Paszat, L. F. (2010) · BMJ · doi:10.1136/bmj.c693 · Cited by 466
Regan, M. M., Leyland-Jones, B., Bouzyk, M., Pagani, O., Tang, W., Kammler, R., Dell’Orto, P., Biasi, M. O., Thürlimann, B., Lyng, M. B., et al. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs125 · Cited by 339
Self-citationCYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
Rae, J. M., Drury, S., Hayes, D. F., Stearns, V., Thibert, J. N., Haynes, B. P., Salter, J., Sestak, I., Cuzick, J., & Dowsett, M. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs126 · Cited by 259
Self-citation
Metadata
- Authors
- Rae, J. M., Sikora, M. J., Henry, N. L., Li, L., Kim, S., Oesterreich, S., Skaar, T. C., Nguyen, A. T., Desta, Z., Storniolo, A. M., Flockhart, D. A., Hayes, D. F., Stearns, V, & for the COBRA investigators
- Venue
- The Pharmacogenomics Journal
- Published
- 2009-05-05
- Volume
- 9
- Issue
- 4
- Pages
- 258-264
- ISSN
- 1470-269X (ISSN-L)
- 1473-1150
- OpenAlex
- W2005868525
- Cited by
- 86
- References
- 6
- FWCI
- 12.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.